Search research articles
Contact Us
Filters
Showing results (561-570 of 755) with videos related to
Page
of 76
Sort By:
The Journal of Rheumatology
|
March 7, 1998
Safety and pharmacokinetics of recombinant human relaxin in systemic sclerosis
J R Seibold, P J Clements, D E Furst, et al.
Annals of the Rheumatic Diseases
|
August 14, 2016
Response to: 'Let's stop fooling ourselves. In RA, only ACR/EULAR criteria define remission and equate with absence of disease!' by Boers
P Emery, C O Bingham, G R Burmester, et al.
Arthritis Research & Therapy
|
April 17, 2019
Study of MRI brain findings and carotid US features in systemic sclerosis patients, relationship with disease parameters
Rania M Gamal, Hanan Sayed M Abozaid, Mohmed Zidan, et al.
Rheumatology (Oxford, England)
|
March 15, 2025
Belumosudil in diffuse cutaneous systemic sclerosis: a randomised, double-blind, open-label extension, placebo-controlled, Phase 2 study
Lorinda Chung, Richard M Silver, Virginia Steen, et al.
European Journal of Internal Medicine
|
September 22, 2019
The Renal Resistive Index in systemic sclerosis: Determinants, prognostic implication and proposal for specific age-adjusted cut-offs
Cosimo Bruni, Edoardo Rosato, Vanessa Maestripieri, et al.
Annals of the Rheumatic Diseases
|
May 12, 2016
Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study
P Emery, C O Bingham, G R Burmester, et al.
The New England Journal of Medicine
|
November 30, 2000
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group
P E Lipsky, D M van der Heijde, E W St Clair, et al.
Clinical Therapeutics
|
July 16, 2003
Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study
Michael H Weisman, Larry W Moreland, Daniel E Furst, et al.
Rheumatology (Oxford, England)
|
May 18, 2022
Biological and clinical insights from a randomized phase 2 study of an anti-oncostatin M monoclonal antibody in systemic sclerosis
Christopher P Denton, Francesco Del Galdo, Dinesh Khanna, et al.
Arthritis Care & Research
|
October 1, 2020
Data-Driven Patient Clustering and Differential Clinical Outcomes in the Brigham and Women's Rheumatoid Arthritis Sequential Study Registry
Jeffrey R Curtis, Michael Weinblatt, Kenneth Saag, et al.
Page
of 76
Search research articles
Search
Showing results (561-570 of 755) with videos related to
Sort By:
Page
of 76
The Journal of Rheumatology
|
March 7, 1998
Safety and pharmacokinetics of recombinant human relaxin in systemic sclerosis
J R Seibold, P J Clements, D E Furst, et al.
Annals of the Rheumatic Diseases
|
August 14, 2016
Response to: 'Let's stop fooling ourselves. In RA, only ACR/EULAR criteria define remission and equate with absence of disease!' by Boers
P Emery, C O Bingham, G R Burmester, et al.
Arthritis Research & Therapy
|
April 17, 2019
Study of MRI brain findings and carotid US features in systemic sclerosis patients, relationship with disease parameters
Rania M Gamal, Hanan Sayed M Abozaid, Mohmed Zidan, et al.
Rheumatology (Oxford, England)
|
March 15, 2025
Belumosudil in diffuse cutaneous systemic sclerosis: a randomised, double-blind, open-label extension, placebo-controlled, Phase 2 study
Lorinda Chung, Richard M Silver, Virginia Steen, et al.
European Journal of Internal Medicine
|
September 22, 2019
The Renal Resistive Index in systemic sclerosis: Determinants, prognostic implication and proposal for specific age-adjusted cut-offs
Cosimo Bruni, Edoardo Rosato, Vanessa Maestripieri, et al.
Annals of the Rheumatic Diseases
|
May 12, 2016
Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study
P Emery, C O Bingham, G R Burmester, et al.
The New England Journal of Medicine
|
November 30, 2000
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group
P E Lipsky, D M van der Heijde, E W St Clair, et al.
Clinical Therapeutics
|
July 16, 2003
Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study
Michael H Weisman, Larry W Moreland, Daniel E Furst, et al.
Rheumatology (Oxford, England)
|
May 18, 2022
Biological and clinical insights from a randomized phase 2 study of an anti-oncostatin M monoclonal antibody in systemic sclerosis
Christopher P Denton, Francesco Del Galdo, Dinesh Khanna, et al.
Arthritis Care & Research
|
October 1, 2020
Data-Driven Patient Clustering and Differential Clinical Outcomes in the Brigham and Women's Rheumatoid Arthritis Sequential Study Registry
Jeffrey R Curtis, Michael Weinblatt, Kenneth Saag, et al.
Page
of 76